3篇
您的检索式：作者名="Helong Hui"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC:a multicenter phase-II trial显示文摘This multicenter phase-II trial aimed to investigate the efficacy,safety,and predictive biomarkers of toripalimab plus chemotherapy as second-line treatment in patients with EGFR-mutant-advanced NSCLC.Patients who failed from first-line EGFR-TKIs and did not harbor T790M mutation were enrolled.Toripalimab plus carboplatin and pemetrexed were administrated every three weeks for up to six cycles,followed by the maintenance of toripalimab and pemetrexed.The primary endpoint was objective-response rate(ORR).Integrated biomarker analysis of PD-L1 expression,tumor mutational burden(TMB),CD8+tumor-infiltrating lymphocyte(TIL)density,whole-exome,and transcriptome sequencing on tumor biopsies were also conducted.Forty patients were enrolled with an overall ORR of 50.0%and disease-control rate(DCR)of 87.5%.The median progression free survival(PFS)and overall survival were 7.0 and 23.5 months,respectively.The most common treatment-related adverse effects were leukopenia,neutropenia,anemia,ALT/AST elevation,and nausea.Biomarker analysis showed that none of PD-L1 expression,TMB level,and CD8+TIL density could serve as a predictive biomarker.Integrated analysis of whole-exome and transcriptome sequencing data revealed that patients with DSPP mutation had a decreased M2 macrophage infiltration and associated with longer PFS than those of wild type.Toripalimab plus chemotherapy showed a promising anti-tumor activity with acceptable safety profiles as the second-line setting in patients with EGFR-mutant NSCLC.DSPP mutation might serve as a potential biomarker for this combination.A phase-III trial to compare toripalimab versus placebo in combination with chemotherapy in this setting is ongoing(NCT03924050). | Tao Jiang Pingyang Wang Jie Zhang Yanqiu Zhao Jianying Zhou Yun Fan Yongqian Shu Xiaoqing Liu Helong Zhang Jianxing He Guanghui Gao Xiaoqian Mu Zhang Bao Yanjun Xu Renhua Guo Hong Wang Lin Deng Ningqiang Ma Yalei Zhang Hui Feng Sheng Yao Jiarui Wu Luonan Chen Caicun Zhou Shengxiang Ren | 2021 | Signal Transduction and Targeted Therapy2021，6，11： | 8 |
| 2 | Potential role of punicalagin against oxidative stress nduced testicular damage显示文摘 | Faiza Rao Hui Tian Wenqing Li Helong Hung Fei Sun | 2016 | Asian Journal of Andrology2016，18，4： | 5 |
| 3 | Integration of coal pyrolysis process with iron ore reduction: Reduction behaviors of iron ore with benzene-containing coal pyrolysis gas as a reducing agent显示文摘An integrated coal pyrolysis process with iron ore reduction is proposed in this article. As the first step, iron oxide reduction is studied in a fixed bed reactor using simulated coal pyrolysis gas with benzene as a model tar compound. Variables such as reduction temperature, reduction time and benzene concentration are studied. The carbon deposition of benzene results in the retarded iron reduction at low temperatures. At high temperatures over800 °C, the presence of benzene in the gas can promote iron reduction. The metallization can reach up to 99% in20 min at 900 °C in the presence of benzene. Significant increases of hydrogen and CO/CO2 ratio are observed in the gas. It is indicated that iron reduction is accompanied by the reforming and decomposition of benzene. The degree of metallization and reduction increases with the increasing benzene concentration. Iron oxide can nearly completely be converted into cementite with benzene present in the gas under the experimental conditions. No sintering is found in the reduced sample with benzene in the gas. | Xin Li Helong Hui Songgeng Li Lu He Lijie Cui | 2016 | Chinese Journal of Chemical Engineering2016，24，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员